Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

Eugene Gholz analyzes the economic and security consequences of China's central position in the global rare-earths market. He discusses the evolution of the rare-earths market, which is critical ...

One nice thing about the rare AirPods Pro updates is that, when new hardware does arrive, so far it’s offered compelling change. AirPods Pro 3 are expected to get: Apple’s budget Apple Watch ...

It works by inhibiting the activation of C3, which plays a key role in the inflammatory process underlying C3G, offering a promising therapeutic option for managing the disease and preventing further ...

The FDA on Tues­day broad­ened the la­bel of No­vo Nordisk’s block­buster di­a­betes drug Ozem­pic.

Her mother, Kelsey, living in Espanola, about 40 minutes west of Sudbury, welcomes all the activity because Iris has a rare, life-long disease which needs weekly treatment in hospital. And doctors ...

Rare diseases are life-altering medical conditions in an individual that are difficult to identify and diagnose because they seem to be heterogeneous in terms of signs and symptoms. Different ...

The Health department is planning to start a clinic for rare diseases at the Government Medical College Hospital, Kozhikode, this year. This was announced by Health Minister Veena George during a ...

AstraZeneca in Canada AstraZeneca employs more than 2,100 people across Canada. Together, AstraZeneca’s R&D Hub and the Alexion, AstraZeneca Rare Disease Development Hub, are leading more than 210 ...

Whole genome sequencing (WGS) is not necessarily a solution for someone with a rare, monogenic disease. Indeed, more than half of families with suspected rare monogenic diseases do not have an ...

MULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, its chief strategy officer and Alexion CEO Marc Dunoyer said in a meeting ...